The Prevalence of Sarcopenia in a Cohort of Haemodialysis Patients and Its Correlation With Mortality

NCT ID: NCT06477978

Last Updated: 2024-06-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

274 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-15

Study Completion Date

2023-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to explore the correlation between the prevalence of sarcopenia and one year mortality amongst patients on maintenance hemodialysis

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In our study , we aim to explore the correlation between the prevalence of sarcopenia and one year mortality among patients on maintenance hemodialysis The lean muscle mass was measured using bio-impedance analysis (BIA ). The hand-grip test was used to measure the function .

Sarcopenia was defined using European Working Group on Sarcopenia in Older people (EWGSOP) definition which involves reduced muscle function and reduced muscle mass

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End-stage Kidney Disease End-stage Renal Disease Dialysis Dependent Chronic Kidney Disease Sarcopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This is cohort prospective study of end stage kidney disease patients on hemodialysis
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

End stage kidney disease patient on maintenance hemodialysis

All patient that have been recruited with have the lean body mass index measured sing the Bio-impedance analysis ( BIA )

Group Type OTHER

Hand grip function testing

Intervention Type DIAGNOSTIC_TEST

The use of Bio-impedance to measure the skeletal muscle mass

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hand grip function testing

The use of Bio-impedance to measure the skeletal muscle mass

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Measuring skeletal body mass using bio-impedance analysis ( BIA)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with End stage kidney disease on maintenance dialysis

Exclusion Criteria

* unable to consent or terminal malignancy
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kasr El Aini Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tarek Samy Abdelaziz

Associate professor of Internal medicine and nephrology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tarek Abdelaziz, PhD

Role: PRINCIPAL_INVESTIGATOR

Kasr El Aini Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kasr Alainy University Hospitals

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MD-119-2020

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.